Literature DB >> 8032860

Clinical observations on the rate of progression of idiopathic parkinsonism.

C S Lee1, M Schulzer, E K Mak, B J Snow, J K Tsui, S Calne, J Hammerstad, D B Calne.   

Abstract

The time course of evolution of clinical deficits has been a traditional guide to the nature of the aetiopathogenesis of neurological disease. We studied the influence of ageing and duration of disease on the natural history of idiopathic parkinsonism (IP). Two hundred and thirty-eight patients with IP were examined while off medication. Bradykinesia scores were analysed against patients' age and duration of disease by multiple regression. There was no significant interaction between the effects of age and of duration (P = 0.923). We conclude that age and duration of symptoms influence the natural history of IP additively and independently. Furthermore, the rate of neuronal death is more rapid in the earlier stages of evolution of the pathology; subsequently, the velocity of progression slows down to approach the rate of attrition produced by normal ageing. This time course has implications for possible models of pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032860     DOI: 10.1093/brain/117.3.501

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  13 in total

1.  The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

Authors:  M A Hely; J G Morris; R Traficante; W G Reid; D J O'Sullivan; P M Williamson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions.

Authors:  Mechelle M Lewis; Guangwei Du; Eun-Young Lee; Zeinab Nasralah; Nicholas W Sterling; Lijun Zhang; Daymond Wagner; Lan Kong; Alexander I Tröster; Martin Styner; Paul J Eslinger; Richard B Mailman; Xuemei Huang
Journal:  J Neurol       Date:  2016-01       Impact factor: 4.849

3.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

4.  Progression of parkinsonism in multiple system atrophy.

Authors:  Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

Review 5.  Progression of motor symptoms in Parkinson's disease.

Authors:  Ruiping Xia; Zhi-Hong Mao
Journal:  Neurosci Bull       Date:  2012-02       Impact factor: 5.203

Review 6.  The natural history of Parkinson's disease.

Authors:  Werner Poewe
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

7.  Imaging nigral pathology and clinical progression in Parkinson's disease.

Authors:  Guangwei Du; Mechelle M Lewis; Suman Sen; Jianli Wang; Michele L Shaffer; Martin Styner; Qing X Yang; Xuemei Huang
Journal:  Mov Disord       Date:  2012-09-24       Impact factor: 10.338

Review 8.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

9.  Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds".

Authors:  Nicholas W Sterling; Ming Wang; Lijun Zhang; Eun-Young Lee; Guangwei Du; Mechelle M Lewis; Martin Styner; Xuemei Huang
Journal:  Neurology       Date:  2016-02-17       Impact factor: 9.910

10.  Older onset essential tremor: More rapid progression and more degenerative pathology.

Authors:  Elan D Louis; Phyllis L Faust; Jean-Paul G Vonsattel; Lawrence S Honig; Claire Henchcliffe; Rajesh Pahwa; Kelly E Lyons; Eileen Rios; Cordelia Erickson-Davis; Carol B Moskowitz; Arlene Lawton
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.